Library / Laws / 114th Congress / House Bills / H.R. 1066
H.R. 1066
To amend the Federal Food, Drug, and Cosmetic Act to promote the use of adaptive trial designs, Bayesian methods, and other innovative statistical methods in clinical protocols for drugs, biological products, and devices, and with respect to the requirement to conduct postapproval studies and clinical trials, and for other purposes.
| Print stage | Date | Size | ⠃ |
|---|---|---|---|
| Introduced in House | 2015-02-25 | 6.3K | ⠃⠗⠋ |